医学美学美容(中旬刊)
醫學美學美容(中旬刊)
의학미학미용(중순간)
MEDICAL AESTHETICS AND COSMETOLOGY
2014年
4期
23-24
,共2页
急性脑出血%全身炎症反应综合症%多脏器功能障碍综合症%依达拉奉%肿瘤坏死因子-α%一氧化氮
急性腦齣血%全身炎癥反應綜閤癥%多髒器功能障礙綜閤癥%依達拉奉%腫瘤壞死因子-α%一氧化氮
급성뇌출혈%전신염증반응종합증%다장기공능장애종합증%의체랍봉%종류배사인자-α%일양화담
Acute intracerebral hemorrhage%System inflammatory response syndrome%Multiple organ disfunction syndrome%Edaravone%Tumor necrosis factor alpha%Interleukin-10%Nitrogen monoxidumin
目的:观察依达拉奉用于治疗急性脑出血(ACH)并发全身炎症反应综合征(SIRS)致多脏器功能障碍综合症(MODS)时肿瘤坏死因子-α(TNF-α)、一氧化氮(NO)的变化。方法:统计59例ACH诱发SIRS、MODS发生率,ACH合并SIRS患者随机分为常规组和依达拉奉组,常规组给予减轻脑水肿、控制血压、血糖等治疗。依达拉奉组加用依达拉奉(商品名为必存,南京先声药业有限公司生产)30mg加入0.9%NS250ml静滴,2次/d共2周。治疗前后比较血清TNF-α、NO水平以及美国国立卫生院卒中患者神经机能缺损评分量表(NIHSS)的比较。结果:1、59例ACH患者诱发SIRS27例、MODS19例,发生率分别为45.76%、32.20%;2、依达拉奉组血清TNF-α、NO水平较常规组下降明显, NIHSS评分减少(P<0.05)。结论:依达拉奉治疗可降低ACH并SIRS、MODS时血清TNF-α、NO水平,其对脑出血时神经元的保护作用与抗炎作用有关。
目的:觀察依達拉奉用于治療急性腦齣血(ACH)併髮全身炎癥反應綜閤徵(SIRS)緻多髒器功能障礙綜閤癥(MODS)時腫瘤壞死因子-α(TNF-α)、一氧化氮(NO)的變化。方法:統計59例ACH誘髮SIRS、MODS髮生率,ACH閤併SIRS患者隨機分為常規組和依達拉奉組,常規組給予減輕腦水腫、控製血壓、血糖等治療。依達拉奉組加用依達拉奉(商品名為必存,南京先聲藥業有限公司生產)30mg加入0.9%NS250ml靜滴,2次/d共2週。治療前後比較血清TNF-α、NO水平以及美國國立衛生院卒中患者神經機能缺損評分量錶(NIHSS)的比較。結果:1、59例ACH患者誘髮SIRS27例、MODS19例,髮生率分彆為45.76%、32.20%;2、依達拉奉組血清TNF-α、NO水平較常規組下降明顯, NIHSS評分減少(P<0.05)。結論:依達拉奉治療可降低ACH併SIRS、MODS時血清TNF-α、NO水平,其對腦齣血時神經元的保護作用與抗炎作用有關。
목적:관찰의체랍봉용우치료급성뇌출혈(ACH)병발전신염증반응종합정(SIRS)치다장기공능장애종합증(MODS)시종류배사인자-α(TNF-α)、일양화담(NO)적변화。방법:통계59례ACH유발SIRS、MODS발생솔,ACH합병SIRS환자수궤분위상규조화의체랍봉조,상규조급여감경뇌수종、공제혈압、혈당등치료。의체랍봉조가용의체랍봉(상품명위필존,남경선성약업유한공사생산)30mg가입0.9%NS250ml정적,2차/d공2주。치료전후비교혈청TNF-α、NO수평이급미국국립위생원졸중환자신경궤능결손평분량표(NIHSS)적비교。결과:1、59례ACH환자유발SIRS27례、MODS19례,발생솔분별위45.76%、32.20%;2、의체랍봉조혈청TNF-α、NO수평교상규조하강명현, NIHSS평분감소(P<0.05)。결론:의체랍봉치료가강저ACH병SIRS、MODS시혈청TNF-α、NO수평,기대뇌출혈시신경원적보호작용여항염작용유관。
. DepartmentofNeurology,MianyangCentralHospital,SichuanProvince,Mianyang621000,China;2. Department of Laboratory, Mianyang Central Hospital,Sichuan Province,Mi-anyang 621000,China;Objective:To observe the ef ects of Edaravone on the serum level of TNF-α、NOin patients of AICH with SIRS、with MODS. Method:59 ACH with SIRS、MODS was randomly devided into two groups:routine treatment group and Edaravone group(treated with edaravone in addition to the routin treatment), Edaravone was injected at a dose of 30mg, twice a day,for 14 days. ) . The serum level of TNF-α、NO and NIHSS scores in two groups were assessed at dif erent point before treatment andtwoweeksafter treatment. Results:The incident rate of AICH with SIRS was 45. 76%. MODS was 32. 2%. TNF-α、NO in serum of patients of Edaravone group decreased significantly(P<0. 05). Conclusion:Edaravone could reduce the serum level of TNF-α、NOand accelerate the recovery of neurological function deficit.